Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Total Debt (2017 - 2026)

Ani Pharmaceuticals' Total Debt history spans 11 years, with the latest figure at $309.1 million for Q4 2025.

  • On a quarterly basis, Total Debt fell 2.88% to $309.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $309.1 million, a 2.88% decrease, with the full-year FY2025 number at $309.1 million, down 2.88% from a year prior.
  • Total Debt hit $309.1 million in Q4 2025 for Ani Pharmaceuticals, down from $312.9 million in the prior quarter.
  • Over the last five years, Total Debt for ANIP hit a ceiling of $318.3 million in Q4 2024 and a floor of $183.4 million in Q1 2021.
  • Historically, Total Debt has averaged $281.9 million across 5 years, with a median of $286.8 million in 2022.
  • Biggest five-year swings in Total Debt: dropped 8.27% in 2021 and later skyrocketed 56.55% in 2022.
  • Tracing ANIP's Total Debt over 5 years: stood at $287.4 million in 2021, then dropped by 0.59% to $285.7 million in 2022, then changed by 0.0% to $285.7 million in 2023, then grew by 11.42% to $318.3 million in 2024, then fell by 2.88% to $309.1 million in 2025.
  • Business Quant data shows Total Debt for ANIP at $309.1 million in Q4 2025, $312.9 million in Q3 2025, and $314.7 million in Q2 2025.